evolocumab

Known as: AMG 145, AMG-145 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low… (More)
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Importance Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin therapy reduces progression of… (More)
  • figure 1
  • table 1
  • figure 2
  • table 3
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Heterozygous familial hypercholesterolaemia is characterised by low cellular uptake of LDL cholesterol, increased… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Homozygous familial hypercholesterolaemia is a rare, serious disorder caused by very low or absent plasma clearance of… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly… (More)
  • table 3
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
IMPORTANCE In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
OBJECTIVES The purpose of this study was assess the effect of evolocumab (AMG 145) on lipoprotein (Lp)(a) from a pooled analysis… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
OBJECTIVES This study sought to evaluate the efficacy and safety of subcutaneous evolocumab compared with oral ezetimibe in… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
OBJECTIVES The aim of this study was to compare biweekly and monthly evolocumab with placebo and oral ezetimibe in patients with… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?